JZL 184

JZL 184 is a potent, selective, and irreversible inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol (2-AG). It increases brain 2-AG levels, leading to cannabinoid-like behavioral effects in animal models. JZL 184 is used as a pharmacological tool to study endocannabinoid signaling, with reported efficacy in preclinical models of anxiety, neuropathic pain, and inflammation. The compound shows >300-fold selectivity for MAGL over fatty acid amide hydrolase (FAAH) and acts as an analgesic and anti-inflammatory agent in animal studies. Sold and distributed for research use; not approved as a therapeutic drug[1][3][4][5][7][8][9].

Other names

MAGL Inhibitor III4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylateMonoacylglycerol Lipase Inhibitor III